BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Staging
19 results:

  • 1.
    Li X; Lu N; Lin L; Chen Y; Yang S; Wang H; Liu X; Wu C; Xue X; Su X; Bai X; Liang T
    J Nucl Med; 2024 Feb; 65(2):206-212. PubMed ID: 38176719
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical application of Al
    Lyu Z; Han W; Zhang Q; Zhao H; Liu S; Wang Y; He J; Zhao C; Tian L; Fu P
    Cancer Imaging; 2023 Sep; 23(1):86. PubMed ID: 37700343
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Initial Evaluation of [
    Watabe T; Naka S; Tatsumi M; Kamiya T; Kimura T; Shintani Y; Abe K; Miyake T; Shimazu K; Kobayashi S; Kurokawa Y; Eguchi H; Doki Y; Inohara H; Kato H; Mori Y; Cardinale J; Giesel FL
    J Nucl Med; 2023 Aug; 64(8):1225-1231. PubMed ID: 37268427
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. 18-Fluoride fluorodeoxyglucose positron emission tomography is impactful in newly diagnosed pancreatic adenocarcinoma.
    Power J; Larcos G
    ANZ J Surg; 2023 Jan; 93(1-2):145-150. PubMed ID: 36582048
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
    Hirmas N; Hamacher R; Sraieb M; Ingenwerth M; Kessler L; Pabst KM; Barbato F; Lueckerath K; Kasper S; Nader M; Schildhaus HU; Kesch C; von Tresckow B; Hanoun C; Hautzel H; Aigner C; Glas M; Stuschke M; Kümmel S; Harter P; Lugnier C; Uhl W; Niedergethmann M; Hadaschik B; Grünwald V; Siveke JT; Herrmann K; Fendler WP
    J Nucl Med; 2023 May; 64(5):711-716. PubMed ID: 36581374
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. PET Imaging of Fibroblast Activation Protein in Various Types of cancer Using
    Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
    J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CT perfusion as a potential biomarker for pancreatic ductal adenocarcinoma during routine staging and restaging.
    O'Malley RB; Cox D; Soloff EV; Zečević M; Green S; Coveler A; Busey JM; Wang CL
    Abdom Radiol (NY); 2022 Nov; 47(11):3770-3781. PubMed ID: 35972550
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography for staging of canine insulinoma: 3 cases (2019-2020).
    Walczak R; Kawalilak L; Griffin L
    J Small Anim Pract; 2022 Mar; 63(3):227-233. PubMed ID: 34811734
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
    Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H
    Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Impact of
    Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
    J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Recommended Workflow Methodology in the Creation of an Interactive Application for Patient's Diagnosed with pancreatic cancer.
    Knight O; Carter CR; Loranger B; Rea PM
    Adv Exp Med Biol; 2019; 1171():85-103. PubMed ID: 31823242
    [TBL] [Abstract] [Full Text] [Related]  

  • 13.
    Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
    J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
    Barreto SG; Loveday B; Windsor JA; Pandanaboyana S
    ANZ J Surg; 2019 May; 89(5):481-487. PubMed ID: 30117669
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Preoperative Assessment of pancreatic cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study.
    Joo I; Lee JM; Lee DH; Lee ES; Paeng JC; Lee SJ; Jang JY; Kim SW; Ryu JK; Lee KB
    Radiology; 2017 Jan; 282(1):149-159. PubMed ID: 27556273
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.
    Kulkarni HR; Prasad V; Kaemmerer D; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():373-8. PubMed ID: 22918769
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
    Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.